1 “...Given issues with the stability of the sponsor's probabilistic analysis (i.e., wide variation...”

2 “...Given issues with the stability of the sponsor's probabilistic analysis (i.e., wide variation...”

3 “... of $1,505,712 per quality-adjusted life-year (QALY) gained and has a 0% probability of being cost-effective...”

4

5

6 “... review of available clinical trial data. The same transition probabilities for eliglustat and the ERTs...”